Modifications in the Anaerob Threshold in Cyclists by Consuming Docosahexaenoic Acid (DHA)

Performance Clinical Trial

— MATCY  

Official title:

Modifications in the Anaerob Threshold in Cyclists (DHA)

Clinical Trial Details — Status: Completed

Administrative data

• NCT number: NCT04128449
• Other study ID #: UCAMCFE-0004
• Status: Completed
• Phase: N/A
• Start date: April 1, 2018
• Est. completion date: June 30, 2018

Study information

• Verified date: October 2019
• Source: Universidad Católica San Antonio de Murcia
• Contact: n/a
• Is FDA regulated: No
• Study type: Interventional

Clinical Trial Summary

In a double-blind, parallel randomized clinical trial with 38 cyclists in whom the performance improvement was determined after the consumption of docosahexaenoic acid for one month.

Recruitment information / eligibility

• Status: Completed
• Enrollment: 38
• Est. completion date: June 30, 2018
• Est. primary completion date: June 30, 2018
• Accepts healthy volunteers: Accepts Healthy Volunteers
• Gender: Male
• Age group: 18 Years to 45 Years

Eligibility

Inclusion Criteria:

• Male between 18 and 75 years old.

• Cyclists who train three or four times a week.

Exclusion Criteria:

• Suffering some type of chronic disease.

• Consume habitually pharmacological treatments that could influence the physiological or biochemical responses to be analyzed in the present work.

• Consumption in the month prior to the start of the study, or during the performance of the same, functional food enriched with omega-3 fatty acids.

• To present during the performance of the stress tests, any of the absolute or relative contraindications dictated by the American College of Sports Medicine (ACSM, 1999) 15 would be duly informed and excluded from the present study.

Related Conditions & MeSH terms

• Performance

Intervention

Dietary Supplement:
• docosahexaenoic acid
5 dragees every 24 hours
• Placebo
5 dragees every 24 hours

Locations

Country	Name	City	State
Spain	Catholic University of Murcia	Murcia

Sponsors (1)

Lead Sponsor	Collaborator
Universidad Católica San Antonio de Murcia

Country where clinical trial is conducted

Spain, 

Outcome

Type	Measure	Description	Time frame	Safety issue
Primary	ergospirometry variable: heart rate	It was done with a bicycle with electromagnetic resistance (Spin Trainer ;Technogym). Heart rate was measured in beats per minute.	The change was evaluated after one month of product consumption.
Primary	ergospirometry variable: absolute oxygen consumption	It was done with a bicycle with electromagnetic resistance (Spin Trainer ;Technogym).It was measured in milliliters per minute	The change was evaluated after one month of consumption of the product
Secondary	ergospirometry variable:respiratory ratio	It was done with a bicycle with electromagnetic resistance (Spin Trainer ;Technogym). Through the oxycon pro jaeger gas analyzer.	The change was evaluated after one month of consumption of the product
Secondary	ergospirometry variable: oxygen equivalent	It was done with a bicycle with electromagnetic resistance (Spin Trainer ;Technogym). Through the oxycon pro jaeger gas analyzer.	The change was evaluated after one month of consumption of the product
Secondary	blood variables: Natremia, potassium, chloremia, calcemia, , bicarbononatemia, ph, lactacidemia.	The following variables were analyzed: The variables are analyzed using the ABL 77 radiometer. The unit of measurement is mmol / L.	The change was evaluated after one month of product consumption.